Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

NCT04163523 | Completed Phase 1

• 1 other identifier: BGB-3111-103
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 5

Brief Summary

Phase 1 study in healthy subjects to determine the effect of food on the pharmacokinetics of BGB-3111.

Conditions

Healthy Volunteers

Keywords

Phase 1, pharmacokinetics safety

Outcome Measures

Primary Outcomes (5)

• Pharmacokinetic Parameter: Plasma concentration of zanubrutinib as measured by area under concentration-time curve (AUC(0-24))

  up to 24 hours

• Pharmacokinetic Parameter: Plasma concentration of zanubrutinib as measured by area under concentration-time curve (AUC(0-∞))

  up to 2 months

• Pharmacokinetic Parameter: Peak Plasma Concentration (Cmax) of zanubrutinib

  up to 2 months

• Pharmacokinetic Parameter: Time to Reach Peak Plasma Concentration (Tmax) of zanubrutinib

  up to 2 months

• Pharmacokinetic Parameter: Half-life Period of zanubrutinib (T1/2)

  up to 2 months

Study Arms (3)

Treatment Sequence 1

EXPERIMENTAL

5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal

Drug: Zanubrutinib

Treatment Sequence 2

EXPERIMENTAL

5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast

Drug: Zanubrutinib

Treatment Sequence 3

EXPERIMENTAL

Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal

Drug: Zanubrutinib

Interventions

Zanubrutinib DRUG

Also known as: BGB-3111

Treatment Sequence 1; Treatment Sequence 2; Treatment Sequence 3

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females between 18 to 65 years of age (inclusive)
• Subjects must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form prior to admission to this study
• Male subjects must agree to use a medically acceptable method of contraception from Screening until 90 days after administration of the last dose of study drug. Medically acceptable methods of contraception include the following: abstinence; a condom in addition to having the female partner use another form of contraception such as medically approved hormonal methods, diaphragm, intrauterine device or a tubal ligation. This requirement may be waived if the Principal Investigator or delegate is satisfied that the subject or partner is sterile (i.e., if female has undergone a hysterectomy, or has undergone a tubal ligation at least 3 months prior to Screening, or is postmenopausal (no menstrual period for at least 12 months prior to Screening); if male has undergone vasectomy at least 6 months prior to Screening). Male subjects agrees not to donate sperm for at least 90 days after administration of the last dose of study drug
• Female subjects of non-childbearing potential measures, meeting at least one of the following criteria:
• amenorrhoeal for 12 months (menopause confirmed by Follicular Stimulating Hormone (FSH) and Luteinising Hormone (LH) levels as defined by the established reference ranges), or
• surgically sterile (e.g. hysterectomy, oophorectomy, tubal ligation for at least 3 months)
• Males and females with a body mass Index (BMI) range 18-35 kg/m2 inclusive.
• Subjects who are healthy as determined by pre-study medical history, physical examination, and 12-Lead ECG
• Subjects who have clinical laboratory test results during the screening period that are within the reference ranges or are clinically acceptable to the Investigator
• Subjects who test negative for HIV, HBV, and HCV by standard serologic tests must be negative at Screening
• Subjects who test negative for drugs of abuse and alcohol tests at screening and admission
• Subjects who are nonsmokers(ex-smokers should have quit smoking at least 6 months prior to screening)

You may not qualify if:

• Subjects who have a history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders that, in the Investigator's opinion, could affect the conduct of the study or the absorption, metabolism or excretion of the study drug
• Subjects who have a history of relevant drug hypersensitivity
• Subjects who have a history of substance abuse, drug addiction or alcoholism
• Subjects who consume more than 14 units of alcohol per week for women and 28 units of alcohol for men
• A QTc at screening, check-in (all periods), and pre and post study drug dosing of greater than 450 msec for males and females
• Subjects with the following laboratory abnormalities (at Screening and check-in of each period): a leucocyte count \< 4.0x10\^9/L, a neutrophil count of \< 2.5x10\^9, lymphocyte count \< 1.2x10\^9/L, Haemoglobin \< 10 g/L, or transaminase levels (ALT, AST) \> ULN
• Subjects who have a significant infection, an acute infection such as influenza, coryzal symptoms, recent upper respiratory tract infection, or known inflammatory process at the time of screening and/or admission
• Subjects who have acute gastrointestinal symptoms at the time of screening and/or admission (e.g. nausea, vomiting, diarrhea, heartburn)
• Subjects who have used prescription drugs within 14 days of first dosing, unless agreed as nonclinically relevant by the Investigator and BeiGene (hormone replacement therapy will be permitted)
• Subjects who have used over the counter medication excluding routine vitamins and herbal supplements (paracetamol \<2 grams/day is acceptable) but including mega dose vitamin therapy and St John's Wort within 7 days of first dosing and throughout the study, unless agreed as nonclinically relevant by the Investigator and BeiGene
• Subjects who have used any investigational drug and /or participated in any clinical trial within 2 months of first dosing
• Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to first dosing. Subjects should not donate blood while on the study and for at least 60 days after last dose of study medication
• Subjects who have consumed food or beverage (including caffeine, alcohol, and grapefruit-containing products) known to interfere with cytochrome P450 within 48 hours prior to first study drug dose
• Subjects who cannot communicate reliably with the investigator or are unlikely to co-operate with the requirements of the study

Sponsors & Collaborators

• BeiGene: lead

Study Sites (5)

Cancer Care Wollongong

Wollongong, New South Wales, 2500, Australia

Location

Austin Health

Heidelberg, Victoria, 3084, Australia

Location

Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia

Location

Nucleus Network

Melbourne, Victoria, 3004, Australia

Location

Linear Clinical Research

Nedlands, Western Australia, 6009, Australia

Location

MeSH Terms

Interventions

zanubrutinib

Study Officials

• William Novotony, MD

  Beigne

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 5, 2019
• First Posted: November 14, 2019
• Study Start: May 25, 2016
• Primary Completion: July 21, 2016
• Study Completion: July 21, 2016
• Last Updated: December 27, 2024

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will share

Locations

AU (5)